What's Happening?
Eurofins CDMO Alphora has announced the integration of advanced Continuous Flow (CF) technology into its Active Pharmaceutical Ingredient (API) manufacturing processes. This development, supported by the National Research Council of Canada Industrial
Research Assistance Program, aims to enhance process control, safety, and production agility. The CF technology, developed in collaboration with a local university, allows for the intensification of complex manufacturing processes that are traditionally challenging to scale. This integration is expected to improve the efficiency and sustainability of API production at Eurofins CDMO Alphora's facility in Mississauga, Ontario.
Why It's Important?
The integration of Continuous Flow technology represents a significant advancement in pharmaceutical manufacturing, offering improved process efficiency and safety. This development is crucial for the pharmaceutical industry, as it addresses the need for more robust and sustainable production methods. By enhancing its manufacturing capabilities, Eurofins CDMO Alphora is better positioned to support innovative pharmaceutical programs and meet the growing demand for high-value, technically challenging APIs. This move also reinforces the company's commitment to operational excellence and innovation in the competitive CDMO market.
